Compare BridgeBio Pharma Inc (BBIO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Novo Nordisk A/S — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Novo Nordisk A/S trades at $49.19 (market cap $218.15B). The key difference: Novo Nordisk A/S is far larger — about 13.4× BridgeBio Pharma Inc's market cap, and Novo Nordisk A/S pays a 3.66% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NVO | |
|---|---|---|
Market Cap | $16.27B | $218.15B |
Sector | Health | Health |
52-Week High | $90.17 | $71.70 |
52-Week Low | $44.81 | $35.29 |
Enterprise Value | $17.82B | $237.11B |
Dividend Yield | — | 3.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
